Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01483378 |
Recruitment Status
:
Completed
First Posted
: December 1, 2011
Results First Posted
: August 9, 2013
Last Update Posted
: August 9, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Herpes Zoster | Other: Choosing to receive the vaccine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 170 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | February 2012 |
Actual Study Completion Date : | February 2012 |

Arm | Intervention/treatment |
---|---|
Subjects who received the vaccine
Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
|
Other: Choosing to receive the vaccine |
No Intervention: Subjects who declined the vaccine |
- Answers to Survey Questions [ Time Frame: January 9, 2012 to February 12, 2012 ]All enrolled patients completed a survey of baseline characteristics, eligibility for the herpes zoster vaccine, and attitudes regarding herpes zoster vaccination. The survey results from patients who agreed to receive the herpes zoster vaccine were compared to the results of patients who declined to be vaccinated.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 60 years of age or older
- Absence of evidence of immune compromise in the medical record
- Ability to speak and read English, Spanish or Chinese and give informed consent
Exclusion Criteria:
- Vulnerable patients, including the cognitively impaired, prisoners and employee
- FDA contraindications for Zostavax vaccine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01483378
United States, New York | |
Bellevue Hospital | |
New York, New York, United States, 10016 | |
NYU Langone Medical Center | |
New York, New York, United States, 10016 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | New York University School of Medicine |
ClinicalTrials.gov Identifier: | NCT01483378 History of Changes |
Other Study ID Numbers: |
11-02029 |
First Posted: | December 1, 2011 Key Record Dates |
Results First Posted: | August 9, 2013 |
Last Update Posted: | August 9, 2013 |
Last Verified: | August 2013 |
Additional relevant MeSH terms:
Herpes Zoster Herpesviridae Infections DNA Virus Infections Virus Diseases |
Vaccines Immunologic Factors Physiological Effects of Drugs |